This webcast is certified for credit.
Release date: March 29, 2018 | Expiration date: March 29, 2019
PARP Inhibitors: Their Role in the Treatment of Ovarian Cancer
Given the recent approval of several PARP inhibitors, as well as the associated volume of emerging data, it is critical that oncologists be able to evaluate the benefits of these agents, select appropriate patients for therapy, and prevent and manage adverse events (AEs). This program will help provide expert guidance to your institution regarding the use of existing PARP inhibitors and companion diagnostics safely and effectively, as well as to plan for optimal integration of new agents and indications into practice when they become available.
The target audience for this activity is gynecologic oncologists, medical oncologists, and other allied healthcare providers caring for patients with ovarian cancer.
After completing this activity, participants should be better able to:
- Evaluate the role of genetic testing and biomarkers for the identification of patients with ovarian cancer to be treated with PARP inhibitors
- Assess the role of PARP in DNA repair, as well as the rationale for targeting PARP in ovarian cancer patients with BRCA-mutated disease
- Appraise data of emerging PARP inhibitors undergoing clinical trial examination for proper use of current available PARP inhibitors
- Identify strategies to prevent and manage side effects of PARP inhibition to improve patient outcomes and adherence
TABLE OF CONTENTS
PARP Inhibitors: Their Role in the Treatment of Ovarian Cancer webcast
Post-activity assessment & evaluation
METHOD OF PARTICIPATION
There are no fees for participating and receiving credit for this activity. During the accredited period, participants must 1) read the learning objectives and faculty disclosures; 2) study the educational activity; 3) complete the pre- and post-activity assessments and evaluation.
Participants who complete the educational activity, pre- and post-activity assessments, and evaluation will receive a certificate of credit.
Materials will be available online through March 2019.
The University of Nebraska Medical Center, Center for Continuing Education, is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
The University of Nebraska Medical Center, Center for Continuing Education, designates this enduring material for a maximum of 1.0 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been planned and implemented in accordance with the accreditation requirements and policies of the Accreditation Council for Continuing Medical Education through the joint providership of the University of Nebraska Medical Center, Center for Continuing Education and Bio Ascend.
This activity is supported by educational grants from AstraZeneca, Clovis Oncology, Inc., and Tesaro, Inc.
Below are the requirements to access online activities:
- Supported operating systems: Windows 7, Windows 8, Windows 10, iPad iOS 9+, and Mac OS X
- Supported Browsers: PC – Chrome, Edge, Firefox, and Internet Explorer 11. Mac – Chrome, Firefox, and Safari. iPad – Safari
- This activity is best experienced with a high-speed Internet connection, such as T1, cable, DSL, etc
Robert L. Coleman, MD, FACOG, FACS
FACULTY AND PLANNING COMMITTEE DISCLOSURES
As a provider accredited by ACCME, the University of Nebraska Medical Center, Center for Continuing Education must ensure balance, objectivity, independence, and scientific rigor in its educational activities. Presenters are encouraged to provide a balanced view of therapeutic options by utilizing either generic names or the trade names of several to ensure impartiality.
All presenters, planners, and others in a position to control continuing medical education content participating in a University of Nebraska Medical Center, Center for Continuing Education activity are required to disclose relationships with commercial interests. A commercial interest is any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients. Disclosure of these commitments and/or relationships is included in activity materials so that participants in the activity may formulate their own judgments in interpreting its content and evaluating its recommendations.
This activity may include presentations in which presenters may discuss off-label and/or investigational use of pharmaceuticals or instruments not yet FDA-approved. Participants should note that the use of products outside currently FDA-approved labeling should be considered experimental and are advised to consult current prescribing information for FDA-approved indications.
All materials are included with the permission of the authors. The opinions expressed are those of the authors and are not to be construed as those of the University of Nebraska Medical Center, Center for Continuing Education or Bio Ascend. The information presented in this activity is not meant to serve as a guideline for patient management; primary references, relevant practice guidelines, and full prescribing information should be consulted.
All disclosed conflicts of interest have been resolved by independent content review.
The planning committee members have no financial relationships to disclose.
Robert L. Coleman, MD, FACOG, FACS
Consultant Fees: AbbVie Inc., Debiopharm Group, Genmab A/S, ImmunoGen, Inc., Merck Sharpe & Dohme Corp., Merrimack Pharmaceuticals, Inc., Millennium Pharmaceuticals, Perthera, Verastem, Inc
Speakers’ Bureau: AstraZeneca, CancerNet, Roche
Advisory Board: AstraZeneca, Bayer AG, Cerulean Pharma Inc., Clovis Oncology, Inc., Eisai-Morphotek, GamaMabs, Genentech, Incyte Corporation, Janssen Global Services, LLC, Novocure, Pfizer Inc, Roche, Vertex Pharmaceuticals Incorporated
Grants/Research Support: Array BioPharma, AstraZeneca, Clovis Oncology, Inc., EMD Serono, Inc. Gradalis, Janssen Global Services, LLC, Merck & Co., Inc.
DISCLOSURE OF OFF-LABEL USE
No product purposes, other than those approved by the FDA, will be discussed.